Company News
Yongchang Qiu

Yongchang Qiu, PhD

President and CEO

Dr. Qiu is a highly experienced drug hunter and developer with 20+ year experiences in drug discovery and development at pharmaceutical and biotechnology companies as well as venture capital investment. He has contributed directly to many successful IND and BLA/NDA filings for a variety of drug modalities, including small molecules, biologics and gene therapies.

Prior to founding Lysoway therapeutics in October 2022, Dr. Qiu was the vice president of preclinical development at Cydan, a rare disease venture/accelerator company which specializes in identifying and investing in rare disease drug assets. Before joining Cydan, Dr. Qiu was head of DMPK and bioanalytical science at Tesaro and a senior director and global head of bioanalytical and biomarker development at Shire, leading a team of 40+ scientists including 25 PhDs and 6 directors. He was responsible for design, development, and implementation of biomarker strategy, immunogenicity risk assessment, as well as safety and diagnostic testing strategies to support 70+ development programs within Shire. Prior to Shire, Dr. Qiu was a director in translational research at Genzyme focusing on preclinical pharmacology and biomarker development for multiple rare disease programs. Dr. Qiu began his career in discovery research at Wyeth in 1998, eventually serving as head of protein chemistry and proteomics.

Dr. Qiu earned his PhD in Pharmaceutical Chemistry and Biopharmaceutical Sciences at University of California at San Francisco, an MS in Organic Chemistry at New York University and a BS in Chemistry from University of Science and Technology of China. Dr. Qiu has authored 70+ peer-reviewed research articles and original patents covering a variety of therapeutics areas.